CUTIA-B (02487.HK): CU-20401 partnership extended beyond Asia
- The supplemental agreement extends the parties' geographical scope from Asia to territories outside Asia.
- Hangzhou Guansu had exclusively assigned all CU-20401 IP and development results for Asia to the Company under the 28 August 2020 agreement.
NewTimeSpace News: On 21 October 2026, Cutia Therapeutics (stock code: 02487) announced a supplemental agreement with Hangzhou Guansu Biotechnology Co., Ltd. that extends their collaboration on CU-20401, a recombinant mutant collagenase, from Asia to territories outside Asia.
Under the agreement, both parties may seek third-party partners in the extended territories for out-licensing or sub-licensing and will strengthen shared clinical, registration and R&D terms to speed development, registration and commercialisation there. Hangzhou Guansu had exclusively assigned to the Company all CU-20401 intellectual property and development results for Asia under the original agreement of 28 August 2020. CU-20401 targets obesity, overweight and local fat accumulation, and completed a Phase II trial in China for submental fat in December 2024.
